.Pharmacolibrary.Drugs.ATC.N.N05CJ03 .Pharmacolibrary.Drugs.ATC.N.N05CJ03| name: | Daridorexant |
| ATC code: | N05CJ03 | route: | oral |
| n-compartments | 2 |
Daridorexant is a dual orexin receptor antagonist (DORA) approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. It acts by selectively blocking the binding of wake-promoting neuropeptides orexin A and B to their receptors OX1R and OX2R. It is currently approved and marketed in the US and EU.
Pharmacokinetics reported for healthy adult subjects after oral administration at therapeutic dose.
Park, J, et al., & Cates PharmD, DW (2023). Daridorexant: Comprehensive Review of A New Oral Agent for the Treatment of Insomnia. The Annals of pharmacotherapy 57(9) 1076–1087. DOI:10.1177/10600280221143794 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36602018